Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 2/20 | 0.51 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.51 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.51 |
| ▸ | PI4KA | P42356 | 1/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.51 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | TTK | P33981 | 1/20 | 0.47 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | MET | P08581 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18449122 | 0.82 | AXL (0.55) | AXLLRRK2PIK3CDPIK3CAPIK3CB | |
| SCHEMBL28432597 | 0.81 | MKNK1 (0.49) | AXLMKNK1MKNK2LRRK2PIK3CD | |
| SCHEMBL844281 | 0.81 | LRRK2 (0.61) | AXLMKNK1MKNK2LRRK2PIK3CD | |
| SCHEMBL15333316 | 0.81 | LRRK2 (0.72) | LRRK2METMAP4K4 | |
| SCHEMBL12919977 | 0.80 | GPR55 (0.50) | MKNK1MKNK2LRRK2PIK3CDPIK3CA | |
| SCHEMBL15950986 | 0.79 | KCNH2 (0.66) | MKNK1MKNK2ACVR1KCNH2KDR | |
| SCHEMBL22917028 | 0.79 | MKNK1 (0.47) | AXLMKNK1MKNK2LRRK2PIK3CD | |
| SCHEMBL967870 | 0.79 | KCNH2 (0.54) | AXLMKNK1MKNK2LRRK2PIK3CD | |
| SCHEMBL16712024 | 0.79 | FYN (0.55) | MKNK1MKNK2LRRK2PIK3CDPIK3CA | |
| SCHEMBL3761234 | 0.79 | GPR55 (0.56) | MKNK1MKNK2LRRK2PIK3CDPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637426-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2026-05-26 | — | — | US | disclosed |
| US-12391676-B2 | BRD4-JAK2 inhibitors | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20250230137-A1 | P300/CBP HAT INHIBITORS | CONSTELLATION PHARMACEUTICALS INC (US) | 2025-07-17 | — | — | US | disclosed |
| EP-3752497-B1 | P300/CBP HAT INHIBITORS | CONSTELLATION PHARMACEUTICALS INC (US) | 2024-07-17 | — | — | EP | disclosed |
| US-20240228502-A1 | 2-PHENYLAMINO PYRROLOPYRIMIDINES AS ACK1 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-07-11 | — | — | US | disclosed |
| CN-114025847-B | Compounds and compositions as modulators of TLR signaling | 神经孔疗法股份有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-11957683-B2 | Bicyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| CN-112218857-B | P300/CBP HAT inhibitors and methods of use thereof | 星座制药公司 | 2023-11-21 | — | — | CN | disclosed |
| EP-3647311-B1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO LTD (CN) | 2023-11-01 | — | — | EP | disclosed |
| CN-112707893-B | 1-cyanopyrrolidine compounds as USP30 inhibitors | 特殊治疗有限公司 | 2023-10-31 | — | — | CN | disclosed |
| US-20130225549-A1 | DIHYDROPTERIDINONES I | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-29 | — | — | US | disclosed |
| US-20120329785-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| US-20120329780-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| WO-2011016472-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES HAVING TTK-INHIBITING ACTIVITY | オンコセラピー・サイエンス株式会社 (JP) | 2011-02-10 | — | — | WO | disclosed |
| WO-2010132015-A1 | NEW COMPOUNDS MODULATING GAMMA-SECRETASE AND THEIR USE IN THE TREATMENT OF ALPHA BETA RELATED PATHOLOGIES, SUCH AS ALZHEIMER'S DISEASE | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132015-A1 | NEW COMPOUNDS MODULATING GAMMA-SECRETASE AND THEIR USE IN THE TREATMENT OF ALPHA BETA RELATED PATHOLOGIES, SUCH AS ALZHEIMER'S DISEASE | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292210-A1 | Novel Compounds for A-Beta-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292210-A1 | Novel Compounds for A-Beta-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292210-A1 | Novel Compounds for A-Beta-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
| WO-2008137102-A2 | METHODS OF MODULATING AMYLOID BETA AND COMPOUNDS USEFUL THEREFOR | TORREYPINES THERAPEUTICS, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228502-A1 | 2-PHENYLAMINO PYRROLOPYRIMIDINES AS ACK1 INHIBITORS | ADCK1, DCK, TNKS2 | AXL 4242/4885MKNK1 75/4885MKNK2 125/4885 |
| US-20130225549-A1 | DIHYDROPTERIDINONES I | BACE1, APP, BACE2 | AXL 4711/4885MKNK1 1616/4885MKNK2 1797/4885 |
| US-11957683-B2 | Bicyclic compounds | SLC10A1, PKD1, CYP11B2 | AXL 4787/4885MKNK1 3375/4885MKNK2 3322/4885 |
| US-20120329780-A1 | Novel kinase inhibitors | LRRK2, MYLK2, MYLK | AXL 672/4885MKNK1 51/4885MKNK2 48/4885 |
| US-20120329785-A1 | Novel kinase inhibitors | LRRK2, MYLK2, MYLK3 | AXL 599/4885MKNK1 67/4885MKNK2 51/4885 |
| US-12637426-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP1, USP10 | AXL 3325/4885MKNK1 2106/4885MKNK2 2890/4885 |
| US-20100292210-A1 | Novel Compounds for A-Beta-Related Pathologies | BACE1, APP, BACE2 | AXL 3932/4885MKNK1 1215/4885MKNK2 1229/4885 |
| US-12391676-B2 | BRD4-JAK2 inhibitors | BRD4, BICRA, JAK2 | AXL 2245/4885MKNK1 466/4885MKNK2 207/4885 |
| US-20250230137-A1 | P300/CBP HAT INHIBITORS | EP300, HDAC1, KAT2A | AXL 4852/4885MKNK1 638/4885MKNK2 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.